Avid Bioservices Inc (CDMO)

[vinmantoo]

entdoc, I think you may be confused.

{{Bavi- was developed as a double-armed MAB vehicle to carry cytotoxins to a specific docking site on vascular endothelial cells, the inner lining cells of blood vessels which nourish cancers and allow them to grow. Bavituximab was originally an anti-angiogenesis MAB in the same category as Avastin, but with a different, exclusive docking site on membrane surface -PS. The idea was to target tumor vasculature. }}

Unless specifically engineered, all IgG monoclonal Abs have two arms which comprise the variable portion of the antibody.



{{Something happened during development: Bavituximab without a payload was immunogenic, stimulating the body's immune system. What happened to loaded Bavi? Rumor has it that when one arm of Bavi is loaded with a small molecule, the other "available" arm cannot bind so readily or solidly to target. }}

Drug conjugates for MAbs can be linked to various portions of the Ab. In fact, multiple conjugates can be added to a single MAb to make it an extremely potent delivery vehicle. If PPHM tried to arm Bavi on one of the variable arms, saw it lose specificity or avidity then stopped rather than try and move the conjugate to other parts of the Ab, like the Fc portion, then they are imbeciles.



{{Again, this is my "understanding" only, but it is said that fully humanized Bavi, now "in production" does not have that issue for reasons more technical than the intent of this post. }}

That sounds like an excuse provided someone who doesn't know what they are talking about. So, why hasn't PPHM announced that the fully humanized Bavi will be made and used as an anti-body drug conjugate?